Literature DB >> 9139873

Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers.

J Niedermeyer1, M J Scanlan, P Garin-Chesa, C Daiber, H H Fiebig, L J Old, W J Rettig, A Schnapp.   

Abstract

The growth of solid neoplasms requires the recruitment of a supporting stroma. In most epithelial cancers, this stromal compartment comprises newly formed blood vessels and abundant, reactive stromal fibroblasts. Tumor stromal fibroblasts are not transformed but differ from resting fibrocytes in normal adult tissues by an altered pattern of gene expression. In human cancers, this includes induction of the cell-surface-bound fibroblast-activation protein (FAP), a member of the serine protease family encoded by the FAP gene on chromosome 2. In this study, we have cloned a complementary DNA for Fap, the murine homologue of FAP. The predicted murine FAP protein, mFAP, shares 89% amino-acid-sequence identity with human FAP, including a perfectly conserved catalytic triad. Cultured mouse embryo fibroblasts and mouse embryonic tissues were found to express Fap transcripts. In addition, the host-derived, fibroblast-rich stroma of human epithelial-cancer xenografts grown in immunodeficient mice also expresses Fap. Sequencing of reverse-transcription-PCR products indicates that 3 distinct Fap splice variants can be detected in tissues. Our findings suggest a close similarity in structure and tissue expression of FAP in different species. By extending the analysis of FAP to the mouse, new in vivo test systems become available for genetic and therapeutic manipulations and for the study of FAP regulation and function in embryonic development and in epithelial cancers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139873     DOI: 10.1002/(sici)1097-0215(19970502)71:3<383::aid-ijc14>3.0.co;2-h

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

2.  Targeted disruption of mouse fibroblast activation protein.

Authors:  J Niedermeyer; M Kriz; F Hilberg; P Garin-Chesa; U Bamberger; M C Lenter; J Park; B Viertel; H Püschner; M Mauz; W J Rettig; A Schnapp
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Fibronectin and beta-catenin act in a regulatory loop in dermal fibroblasts to modulate cutaneous healing.

Authors:  Kirsten A Bielefeld; Saeid Amini-Nik; Heather Whetstone; Raymond Poon; Andrew Youn; Jian Wang; Benjamin A Alman
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

4.  Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases.

Authors:  Shu Y Qi; Pierre J Riviere; Jerzy Trojnar; Jean-Louis Junien; Karen O Akinsanya
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

5.  Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-α in transformed astrocytic cells.

Authors:  Eva Balaziova; Petr Busek; Jarmila Stremenova; Lucie Sromova; Evzen Krepela; Libuse Lizcova; Aleksi Sedo
Journal:  Mol Cell Biochem       Date:  2011-04-28       Impact factor: 3.396

6.  Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.

Authors:  Pui-Chi Lo; Juan Chen; Klara Stefflova; Michael S Warren; Roya Navab; Bizhan Bandarchi; Stefanie Mullins; Ming Tsao; Jonathan D Cheng; Gang Zheng
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

7.  Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.

Authors:  W Nathaniel Brennen; D Marc Rosen; Alcides Chaux; George J Netto; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2014-07-22       Impact factor: 4.104

8.  Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.

Authors:  Jiping Zhang; Matthildi Valianou; Heidi Simmons; Matthew K Robinson; Hyung-Ok Lee; Stefanie R Mullins; Wayne A Marasco; Gregory P Adams; Louis M Weiner; Jonathan D Cheng
Journal:  FASEB J       Date:  2012-10-26       Impact factor: 5.191

9.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

10.  Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.

Authors:  C Kloft; E-U Graefe; P Tanswell; A M Scott; R Hofheinz; A Amelsberg; M O Karlsson
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.